Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.

<h4>Background</h4>Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arjan van der Tol, Wim Van Biesen, Steven Van Laecke, Kris Bogaerts, Koen De Lombaert, Hans Warrinnier, Raymond Vanholder
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3003a43713334de682f2019fb67f4a28
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3003a43713334de682f2019fb67f4a28
record_format	dspace
spelling	oai:doaj.org-article:3003a43713334de682f2019fb67f4a282021-11-18T07:27:58ZStatin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.1932-620310.1371/journal.pone.0031639https://doaj.org/article/3003a43713334de682f2019fb67f4a282012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22359611/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease.<h4>Methodology/principal findings</h4>We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients. MAU was defined as albuminuria ≥20 mg/l. A propensity score was created to correct for "bias by indication" to receive a statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication. Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34-3.01). The association between statin use and MAU remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82, 95%CI: 1.14-2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00-3.66) and smoking (OR: 1.49, 95%CI: 0.99-2.26) were associated with MAU.<h4>Conclusions</h4>Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses.Arjan van der TolWim Van BiesenSteven Van LaeckeKris BogaertsKoen De LombaertHans WarrinnierRaymond VanholderPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 2, p e31639 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Arjan van der Tol Wim Van Biesen Steven Van Laecke Kris Bogaerts Koen De Lombaert Hans Warrinnier Raymond Vanholder Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
description	<h4>Background</h4>Microalbuminuria (MAU) is considered as a predictor or marker of cardiovascular and renal events. Statins are widely prescribed to reduce cardiovascular risk and to slow down progression of kidney disease. But statins may also generate tubular MAU. The current observational study evaluated the impact of statin use on the interpretation of MAU as a predictor or marker of cardiovascular or renal disease.<h4>Methodology/principal findings</h4>We used cross-sectional data of ERICABEL, a cohort with 1,076 hypertensive patients. MAU was defined as albuminuria ≥20 mg/l. A propensity score was created to correct for "bias by indication" to receive a statin. As expected, subjects using statins vs. no statins had more cardiovascular risk factors, pointing to bias by indication. Statin users were more likely to have MAU (OR: 2.01, 95%CI: 1.34-3.01). The association between statin use and MAU remained significant after adjusting for the propensity to receive a statin based on cardiovascular risk factors (OR: 1.82, 95%CI: 1.14-2.91). Next to statin use, only diabetes (OR: 1.92, 95%CI: 1.00-3.66) and smoking (OR: 1.49, 95%CI: 0.99-2.26) were associated with MAU.<h4>Conclusions</h4>Use of statins is independently associated with MAU, even after adjusting for bias by indication to receive a statin. In the hypothesis that this MAU is of tubular origin, statin use can result in incorrect labeling of subjects as having a predictor or marker of cardiovascular or renal risk. In addition, statin use affected the association of established cardiovascular risk factors with MAU, blurring the interpretation of multivariable analyses.
format	article
author	Arjan van der Tol Wim Van Biesen Steven Van Laecke Kris Bogaerts Koen De Lombaert Hans Warrinnier Raymond Vanholder
author_facet	Arjan van der Tol Wim Van Biesen Steven Van Laecke Kris Bogaerts Koen De Lombaert Hans Warrinnier Raymond Vanholder
author_sort	Arjan van der Tol
title	Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
title_short	Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
title_full	Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
title_fullStr	Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
title_full_unstemmed	Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.
title_sort	statin use and the presence of microalbuminuria. results from the ericabel trial: a non-interventional epidemiological cohort study.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/3003a43713334de682f2019fb67f4a28
work_keys_str_mv	AT arjanvandertol statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT wimvanbiesen statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT stevenvanlaecke statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT krisbogaerts statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT koendelombaert statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT hanswarrinnier statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy AT raymondvanholder statinuseandthepresenceofmicroalbuminuriaresultsfromtheericabeltrialanoninterventionalepidemiologicalcohortstudy
_version_	1718423399408074752

Statin use and the presence of microalbuminuria. Results from the ERICABEL trial: a non-interventional epidemiological cohort study.

Ejemplares similares